All News

The researchers found that even with low amounts or no amount of neutrophils present in the peripheral blood, patients still exhibited active disease.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, talks about the increase of eosinophilic esophagitis, or EoE, along with other allergic conditions.

Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, describes the main challenges to identifying, measuring, and reducing use of low-value care and the granular data needed to solve these challenges.

Human papillomavirus surrogate marker p16 was identified as a potential prognostic biomarker for standard-of-care immune checkpoint blockade therapy response in non-oropharyngeal head and neck squamous cell carcinoma.

Authors described recent therapeutic developments in heart failure with preserved ejection fraction (HFpEF) and proposed a conceptual framework for more targeted treatment.

Investigation into myeloid-related protein 8/14 (MRP8/14) serves as an important next step of translational research to discovering a diagnostic biomarker for systemic juvenile idiopathic arthritis.

Korean patients with moderate-to-severe atopic dermatitis achieved and maintained markedly improved skin clearance with dupilumab treatment in a real-world setting, including in the face and hands.

David Yeomans, PhD, associate professor of anesthesiology, perioperative, and pain medicine at Stanford University School of Medicine, discusses the challenges of evaluating pain associated with migraine.

The CDC recommends children aged 12 years and up to receive COVID-19 vaccine boosters; nearly 2 million children develop asthma as a result of breathing in an air pollutant; nurses unions sue the Biden administration for withdrawing COVID-19 worker protections.

Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, explains the National Comprehensive Cancer Network (NCCN) update on COVID-19 vaccines and prevention.

Patients with diabetes living in rural or deprived regions in the United States are less likely to achieve optimal care for their condition, according to a new cross-sectional study.

A review of published literature revealed which diet methods and forms of physical activity are most effective at improving patient-reported outcomes in patients with multiple sclerosis (MS).

The Biden administration doubled its order of Pfizer’s COVID-19 antiviral drug; California is now the first state to require health insurance plans to cover at-home STI tests; the Supreme Court will hear in-person arguments Friday to decide whether to block federal vaccine mandates.

The study points to the challenges of treating chronic obstructive pulmonary disease in a remote region in a country with a high smoking rate.

School closures during the first wave of the COVID-19 pandemic in Switzerland were linked with longer sleep duration and improved health-related quality of life in high school students.

This new study from India investigated outcomes as they pertained to preterm birth, low birth weight, and infant growth measures up to 1 year post delivery.

The respiratory complications of spinal muscular atrophy are well-researched, but a new study provides insight into nonrespiratory complications that may be just as crucial.

HIV infection and antiretroviral therapy (ART) may influence subdominant gut bacteria in association with immune status in children living with HIV.

Treatment with the interleukin-36 inhibitor spesolimab was associated with improved lesion clearance vs placebo after one week, but also a greater incidence of infection and systemic drug reactions.

The update recommends that patients who receive CAR T-cell therapy wait 3 months before getting a COVID-19 vaccine.

Cullinan Oncology’s CLN-081 today received a Breakthrough Therapy Designation from the FDA for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC).

At least 8 biosimilars were approved in Canada over the past 12 months, as policy makers made a strong push for biosimilar acceptance, which led to a change in prescribing patterns.

The patient had no obvious pulmonary symptoms, but a routine chest X-ray helped investigators arrive at the diagnosis.

US cases of COVID-19 surge to record levels; FDA expands eligibility for Pfizer/BioNTech booster doses to children ages 12 to 15 years old; Israeli study finds fourth shot of COVID-19 vaccine effective and safe.

David Ramsey, MD, PhD, MPH, outlines what may have contributed to patients' decisions to return to in-person eye care following a telehealth appointment.

In preclinical studies, HDAC inhibitors have been shown to have immunomodulatory effects— including enhancing antigen presentation, recruiting T cells into tumors, and promoting T-cell function—when combined with PD-1 inhibitors.

Further investigation into the mechanisms of endothelial dysfunction and its role in the pathogenesis of pulmonary arterial hypertension (PAH) may lead to more targeted therapies against the disease.

Tennessee Oncology appointed Stephen Schleicher, MD, MBA, as Chief Medical Officer (CMO), with president Natalie Dickson, MD, being promoted from CMO to Chief Strategy Officer (CSO).